Business Wire

NY-MEDIAOCEAN

6.3.2024 10:01:33 CET | Business Wire | Press release

Share
Flashtalking by Mediaocean Announces New Exclusive International Partnerships Covering 89 Markets

Mediaocean, the mission-critical platform for omnichannel advertising, today announced six new partnerships for its Creative Ad Tech platform, Flashtalking, bringing its market leading solutions to more customers in a range of key markets around the world. The agreements provision for primary ad serving, creative personalization, cross-channel measurement and verification across open web display, mobile, audio, video, digital out-of-home, and connected TV.

Collectively, the new activation partners support advertisers in 89 different countries, significantly expanding Flashtalking’s footprint following a surge in adoption after the announcement that Amazon was deprecating its Sizmek ad server. Each of these companies brings deep experience in the ad serving market, having previously supported brands and agencies using Amazon/Sizmek.

Founded in 2001 and acquired by Mediaocean in 2021, Flashtalking is the leading independent ad tech platform, bridging creative and media teams with intelligent, audience-aware insights and workflows at scale and across channels. The Flashtalking platform provides AI and automation to connect the silos between teams for more efficient production, versioning, and distribution of creative.

The new partners include Tailwind, which operates in 36 markets across Central and South Eastern Europe, the Nordics and Middle East North Africa (MENA), empowering businesses to fast track their marketing with technology integrations, strategic consultation, and professional services, as well as Box Digital, a South Africa-based digital advertising services business with customers spanning 8 sub-Saharan African countries.

A partnership with Adsmovil will bolster Flashtalking’s operations within 33 markets across Latin America (LATAM), through a business uniquely focused on Hispanic and Brazilian audiences which currently serves over 4 billion impressions per month. Meanwhile, a new relationship with Adsonice, will grow Flashtalking’s presence across Europe.

Additionally, an agreement with Escape Velocity, a digital media technology services company that supports agencies and advertisers, will scale Flashtalking in India, Korea, Bangladesh, and Sri Lanka while eTechSol will help serve customers in Pakistan.

Simon Thorne, MD EMEA for Flashtalking, commented: “We’ve seen huge appetite for a truly intelligent, dynamic approach to managing and activating creative campaigns. Advertisers need to enable deep personalization, ensuring the most relevant and impactful brand messages reach the right consumers at the right moment, and they want to do it via a single integrated platform. Today’s announcement really cements our position as being the best solution to deliver that on a global level.”

Coming in the wake of Amazon’s announcement that it will be shuttering its ad serving service, these new partnerships represented a unique opportunity to combine Flashtalking’s best-in-class advertising technology with in-market experts who can offer deep local insights and a highly mature ad serving knowledge base.

Flashtalking was recently named a winner of G2 2024 Best Software Awards for Marketing & Digital Advertising Products based on 300+ authenticated customer reviews. The platform was ranked a leader in Enterprise Creative Management Platforms, Cross-Channel, Video, Mobile, Display, and Social Media Advertising.

Georgia Brammer, MD JAPAC for Flashtalking, added, “We’re thrilled to be able to build these new relationships in so many important markets. We’ve been impressed by the drive and knowledge represented by the teams at all of these businesses. This is, on multiple fronts, a time of change in the global advertising sector and, from conversations with major advertisers, the growth potential we’re seeing in further developing this global network is already proving to be really powerful.”

Odysseas Ntotsikas, Managing Partner of Tailwind, stated, “True to Tailwind’s mission to ‘Drive business fast forward’ the power of creative has proved to be the variable with the biggest impact in an omnichannel marketer’s stack. Through this strategic partnership with global leader Flashtalking, we fortify over a decade of operational excellence in empowering hundreds of regional marketers with creative personalization and digital advertising intelligence to win the only war that matters today, the war for attention.”

Alberto Pardo, Founder & CEO of Adsmovil, said, “We, at Adsmovil, have been committed to driving relevance and value to our clients since our inception. Flashtalking furthers our mission and expands the opportunity to better serve clients with personalization based on real-time variables, driving greater congruence and resonance, and a higher advertiser ROI. We are very excited about our partnership.”

Raghu Seelamsetty, MD of Escape Velocity, added, “Escape is delighted to be partnering with Flashtalking. The partnership is well poised to take advantage of the growth of CTV and social media in these fast growing markets. Flashtalking’s market leading technology combined with Escape’s market reach and service capabilities will enable us to deliver world class solutions to our clients.”

About Flashtalking by Mediaocean

Flashtalking unleashes the power of creative to make media work better. As the leading independent platform for personalization and intelligence across all marketing channels, our Creative Ad Tech bridges the gap between creative and media. We provide AI and automation to connect the silos between teams and deliver more efficient production, versioning, and distribution of creative. Our solutions operate at scale across CTV, Video, Display, Social, Native, Audio, DOOH, and Retail Media channels. As part of Mediaocean, Flashtalking is tied into the industry’s core ad infrastructure for omnichannel planning, buying, and billing. Visit flashtalking.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305248528/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye